Collaboration Agreements

The Partnership Hub, administered by BIO Ventures for Global Health (BVGH), plays the crucial role facilitating specific collaboration agreements among Members. The BVGH team works closely with members to identify researchers’ needs for intellectual property (IP) and related resources to advance product development, finds other members that may be able to meet these needs, and then helps to forge mutually beneficial collaborations with clearly defined roles, responsibilities, and objectives.

These collaborations cover a range of areas that include the sharing of data and services (such as access to company research facilities, screening of compounds, hosting of scientists) as well as other forms of expertise.

To date, 44 various collaboration agreements under the terms of WIPO Re:Search have been facilitated by BVGH. As collaborations are being negotiated on an ongoing basis, the list below identifies agreements in place at a given time. Please check this page regularly for updated information.

WIPO Re:Search Established Agreements

  Collaboration Description Members Agreement Status
1 Develop and test a diagnostic for helminthes Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) and Stanford University   Agreement in place. This collaboration will enable the sharing of stool samples to support Stanford’s helminth diagnostic product development and testing.  
2 MetAp-1 inhibitor drug development for tuberculosis GlaxoSmithKline (GSK) and Center for World Health and Medicine (CWHM) Collaboration in place. GSK has shared information and data with CWHM as well as providing insights into the development of MetAp-1 inhibitors for tuberculosis. This information sharing resulted in approximate savings of $50,000 and three months of FTE time for CWHM.  
3 Computational chemistry support for tuberculosis drug candidates AstraZeneca (AZ) and iThemba Pharmaceuticals Agreement in place. AZ is providing computational and predictive chemistry know-how and support to iThemba in order to improve compound characteristics for tuberculosis drug candidates.  
4 Cysteine protease inhibitors library for multiple neglected disease drug discovery AstraZeneca (AZ) and University of California at San Francisco (UCSF) Agreement in place. AZ is providing UCSF with a diverse cysteine protease inhibitor compound library to screen against T. cruzi, T. brucei, P. falciparum and S. mansoniAgreement was amended to include screening of compounds against hookworm.  
5 Glycogen Synthase Kinase 3 (GSK-3) inhibitors for kinetoplastids drug discovery   AstraZeneca (AZ) and University of Dundee Agreement in place. AZ is providing a GSK-3 inhibitor compound library to Dundee to screen against Kinetoplastids.   
6 In-kind support from the NIH for dengue drug discovery National Institutes of Health (NIH) and Emory University     Agreement in place. This agreement provides Emory University researcher with biology expertise and support from the NIH for RNA-dependent RNA polymerase inhibitor program for dengue. The characterization of the compounds included screening against the Rift Valley Fever virus.  
7 Characterize pre-clinical compounds for malaria GlaxoSmithKline (GSK) and University of Washington (UW) Agreement in place. This agreement enables the sharing of confidential information and transfer of UW compounds to GSK. Compounds will be re-profiled at GSK in Tres Cantos for transmission blocking in malaria.  
8 Fabl inhibitor compound structures and data sharing for Shigella AstraZeneca (AZ) and Anacor Collaboration in place. AZ has shared knowledge and dataon Fabl inhibitors and compound structures to inform and support Anacor’s development of products for Shigella.  
9 Compounds for schistosomiasis Merck and University of California at San Francisco (UCSF) Agreements in place. Confidentiality agreement enabled discussions around compound selection. Collaborative study agreement allows for the sharing of compounds with UCSF for screening against S. mansoni.  
10 Research collaboration around multi-kinase inhibitors in malaria   GlaxoSmithKline (GSK) and University of Washington (UW) Agreement in place. GSK to work collaboratively with UWto identify lead compound in a series. The initial compounds screened at UW were from the Tres Cantos Anti-Malaria (TCAMS) data set.  
11 Co-development of onchocerciasis diagnostic PATH and Kumasi Center for Collaborative Research in Tropical Medicine (KCCR)   Agreement in place. Confidentiality agreement will enable discussions and planning for co-development of a novel onchocerciasis diagnostic.
12 Research collaboration around tuberculosis drug discovery   AstraZeneca (AZ) and Anacor Agreement in place. Anacor compounds will be screened against AZ tuberculosis targets.  
13 Sharing of preclinical compound libraries for malaria   AstraZeneca (AZ) and Liverpool School of Tropical Medicine   Agreement in place. This agreement will enable sharing of AZ’s advanced preclinical and clinical compounds for screening against the malaria parasite.  
14 Sharing of CYP51 inhibitors for screening against kinetoplastids   AstraZeneca (AZ) and University of California San Francisco (UCSF) Agreement in place. Non azole CYP51 inhibitors and a diverse set of compounds from AZ will be made available to UCSF for screening against Chagas and Leishmaniasis.
15 Testing of anti-helminthic compounds in drug-resistant mutants AstraZeneca (AZ) and McGill University Agreement in place. AZ compounds that were promising in a DNDi phenotypic anti-helminth screen with be tested at McGill University against C. elegans mutant strains to elucidate the mechanism of action.  
16 Expertise and advise will be shared to optimize natural product derived compounds Infectious Disease Research Institute (IDRI ) and South African Medical Research Council (MRC))   Agreement in place. IDRI will share expertise and provide advice to improve solubility and bioavailability of anti-TB compounds developed at MRC /University of Cape Town.
17 Sharing of calcium channel blocker compound Eisai and University of Dundee Agreement in place. Eisai has transferred a compound to the University of Dundee under an MTA for testing against the malarial parasite.  
18 Sharing of proteasome inhibitor compound Eisai and University of Dundee Agreement in place. Eisai has transferred a compound to the University of Dundee under an MTA for testing against the malarial parasite.
19 Sharing of compounds to support anti-diarrheal product development   Pfizer and Center for World Health and Medicine (CWHM) Agreement in place. Pfizer will provide two compounds to CWHM for evaluation in a rat diarrhea model.
20 Advice and knowledge sharing for peptide formulation AstraZeneca (AZ) and Stanford University Collaboration in place. AZ (MedImmune) will share technical know-how with Stanford researcher to enable peptide formulation for cutaneous leishmaniasis.  
21 Advice and knowledge sharing for anti-fungal formulation   Eisai and University of Kansas (KU) Agreement in place. One way CDA enabled sharing of expertise and ideas to address formulation issues. KU faculty member confirmed that all strategies had been comprehensively explored by Eisai.  
22 Sharing of reagent for dengue research   Novartis and McMaster University Agreement in place. Novartis shared a polyclonal anti-dengue antibody with a McMaster University researcher.  
23 Computational Support for compounds against Human African Trypanosomiasis (HAT)   AstraZeneca (AZ) and Northeastern University Collaboration in place. AZ will provide computational prediction of blood brain barrier penetration for a set of compounds from Northeastern University.  
23 Testing of neutral endopeptidase inhibitors for use against acute secretory diarrhea (ASD)   Sanofi & Center for World Health & Medicine (CWHM) Agreement in place. Sanofi has granted access to its neutral endopeptidase inhibitors for evaluation in CWHM’s animal model.  
24 Fabl inhibitor compound structures and data sharing for Shigella AstraZeneca (AZ) and Anacor Collaboration in place. AZ has shared knowledge and data on Fabl inhibitors and compound structures to inform and support Anacor’s development of products for Shigella.
25 Sharing of inhibitors of M. tuberculosis for screening against Buruli ulcer AstraZeneca (AZ) and Swiss Tropical and Public Health Institute (Swiss TPH) Agreement in place. AZ will provide compounds including their compound in clinical trials against TB for screening against M. ulcerans, the causative agent for Buruli ulcer.
26 Sharing of protein purification know how Merck and Emory University Agreement in place. Merck will share know how for membrane bound protein purification with a researcher working on tuberculosis at Emory.
27 Access to compounds for onchocerciasis and lymphatic filariasis treatment AZ and Liverpool STM Agreement in Place: AZ is providing Liverpool STM scientists with access to its labs and high-throughput screens of compounds to test against Wolbachia in order to identify new onchocerciasis and lymphatic filariasis therapies.
28 Structure Activity Relationship advice for HAT inhibitors Eisai and Northeastern Agreement in Place: A discussion between Northeastern and Eisai to obtain advice from Eisai on SARs for the design of phosphodiesterase inhibitors of HAT.
29 Natural products for tuberculosis AstraZeneca (AZ) and Eskitis Agreement in place: Eskitis will share its natural product library with AZ Bangalore to screen against tuberculosis.
30 Compound libraries for anti-helminthic HTS AstraZeneca (AZ) and McGill Agreement in place: AZ will provide McGill with ~10,000 diverse compounds to test against C. elegans. Data from the screen will be included in a re-submission of a Wellcome Trust grant application.
31 Providing advice on adjuvant design Eisai and Infectious Disease Research Institute (IDRI) Agreement in place: Eisai provided IDRI with advice regarding parameters to consider during vaccine adjuvant design.
32 Kinase inhibitors for malaria GlaxoSmithKlein (GSK) and National Institute of Immunology, India (NII) Agreement in place: GSK will share kinase inhibitors with NII to use to study various molecular pathways in malaria.
33 MOU to explore several collaboration opportunities Kumasi Centre for Collaborative Research, Ghana (KCCR) and Northeastern University Agreement in place: An MOU was signed between KCCR and Northeastern that will enable the institutions to explore grant opportunities together, develop exchange between students, and conduct collaborative lab projects together.
34 Natural products for tuberculosisNatural products for tuberculosis National Institute of Health (NIH) and Infectious Disease Research Institute (IDRI) Agreement in place: NIH will provide IDRI with natural product compounds to screen against tuberculosis.
35 Sharing investigators brochure Pfizer and 60 Degrees Pharmaceuticals (60P) Agreement in place: Pfizer will provide its investigators brochure for a discontinued compound to 60P. 60P is hoping to repurpose the drug as a dengue treatment.
36 Anti-inflammatory compounds for malaria Pfizer and McGill Agreement in place: Pfizer will share JAK inhibitors with McGill to screen in a cerebral malaria model.
37 Providing HMG Co-A reductase inhibitors for schistosome research Merck and University of California, San Francisco (UCSF) Agreement in place: Merck will share compounds with UCSF to screen against schistosomiasis
38 Sharing set of compounds for malaria AZ and Liverpool STM Agreement in place:  AZ will share an additional set of compounds with Liverpool STM to screen against malaira.
39 Kinase inhibitors for tuberculosis GSK and NII Agreement in place: GSK will share kinase inhibitors with NII to study tuberculosis metabolic pathways.
40 Kinase inhibitors for schistosomiasis GSK and UCSF Agreement in place: GSK will share a set of kinase inhibitors with UCSF to test against schistosomiasis.
41 Kinase inhibitors for schistosomiasis GSK and UCSF Agreement in place: GSK will share a second set of kinase inhibitors with UCSF to test against schistosomiasis.
42 Sharing investigators brochure

Pfizer and PATH

Agreement in place: Pfizer will share an investigator brochure with PATH. PATH aims to repurpose a drug to treat diarrheal diseases.
43 Sharing compounds to support anti-diarrheal product development

Sanofi and CWHM

Agreement in place: Sanofi provided two compounds to CWHM to evaluate in a rat diarrhea model.
44 Testing paper microscope for malaria U. of Lagos and Stanford Agreement in place: The University of Lagos will host two researchers from Stanford to test their paper microscope using field samples.

 

Hosting Agreements

A generous grant made available by IP Australia, the Australian Government agency that administers IP rights and legislation relating to patents, trademarks, designs and plant breeder's rights, has allowed WIPO Re:Search to develop a program under which developing country scientists are ‘hosted’ by developed country members of WIPO Re:Search. These ‘hosting arrangements’ are facilitated by BIO Ventures for Global Health, which identifies and screens candidates and matches them with WIPO Re:Search Members that are willing to place these scientists in their research labs. To date, five such arrangements are underway.

Partners Opportunity /Research Focus Duration
University of California San Francisco (UCSF) and Kumasi Center for Collaborative Research in Tropical Medicine (KCCR) / Kwame Nkrumah University, Ghana Dr. Christian Agyare from Ghana is working in Dr. Conor Caffrey’s laboratory at UCSF. Dr. Agyare will participate in schistosomiasis drug and diagnostic development. He will gain exposure to leading edge academic drug discovery and parasitology research. August - December 2013, and March to September 2014.
Stanford University and Theodor Bilharz Research Institute, Egypt Dr. Olfat Hammam is conduct research in the laboratory of Professor Michael Hsieh at Stanford University. Dr. Hammam will work in the area of schistosomal bladder carcinogenesis and fibrosis building on her experience as a pathologist. Joint publication of the work done is planned. June 2013 – May 2014
Novartis and University of Lagos Medical School Dr. Wellington Oyibo, a malaria specialist, is at Novartis headquarters in Basel, Switzerland. Novartis is providing training in the practical management of the R&D drug discovery process. August – October 2013
Novartis and University of Buea, Cameroon Dr. Fidelis Cho-Ngwa, Head, Biochemistry and Molecular Biology at University of Buea, Cameroon, is at Novartis headquarters in Basel, Switzerland. Dr. Cho-Ngwa, is combining training in the management of R&D with direct work in the laboratory. August – October 2013
AstraZeneca (Bangalore, India facility) and MRC South Africa /University of Cape Town Ms. Krupa Naran is working at the AstraZeneca Bangalore working in the area of discovery of inhibitors for TB targets. She will gain valuable experience on compound screening and assay development, focusing on TB, a major public health issue in South Africa. August – October 2013

 

WIPO Re:Search

Technical Advisor to WIPO